{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:45:50Z","timestamp":1792154750648,"version":"4.4.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI14\/00639"],"award-info":[{"award-number":["PI14\/00639"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI14\/00918"],"award-info":[{"award-number":["PI14\/00918"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI17\/01056"],"award-info":[{"award-number":["PI17\/01056"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018812","name":"Instituto de Investigaci\u00f3n Marqu\u00e9s de Valdecilla","doi-asserted-by":"publisher","award":["NCT0235832"],"award-info":[{"award-number":["NCT0235832"]}],"id":[{"id":"10.13039\/501100018812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018812","name":"Instituto de Investigaci\u00f3n Marqu\u00e9s de Valdecilla","doi-asserted-by":"publisher","award":["NCT02534363"],"award-info":[{"award-number":["NCT02534363"]}],"id":[{"id":"10.13039\/501100018812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jpsychires.2022.07.015","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T06:31:49Z","timestamp":1657089109000},"page":"292-299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Naturalistic study on the use of clozapine in the early phases of non-affective psychosis: A 10-year follow-up study in the PAFIP-10 cohort"],"prefix":"10.1016","volume":"153","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4394-2842","authenticated-orcid":false,"given":"Lara","family":"Moreno-Sancho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6782-6515","authenticated-orcid":false,"given":"Maria","family":"Juncal-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5478-3376","authenticated-orcid":false,"given":"Javier","family":"V\u00e1zquez-Bourgon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0627-1827","authenticated-orcid":false,"given":"Victor","family":"Ortiz-Garcia de la Foz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Mayoral-van Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Tordesillas-Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8027-6546","authenticated-orcid":false,"given":"Esther","family":"Setien-Suero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Ayesa-Arriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicto","family":"Crespo-Facorro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2022.07.015_bib1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0920-9964(92)90003-N","article-title":"Reliability and validity of a depression rating scale for schizophrenics","volume":"6","author":"Addington","year":"1992","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib2","series-title":"The Scale for the Assessment of Positive Symptoms (SAPS)","author":"Andreasen","year":"1984"},{"key":"10.1016\/j.jpsychires.2022.07.015_bib3","series-title":"Scale for the Assessment of Negative Symptoms (SANS)","author":"Andreasen","year":"1983"},{"key":"10.1016\/j.jpsychires.2022.07.015_bib4","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rationale for consensus","volume":"162","author":"Andreasen","year":"2005","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib5","article-title":"Clozapine versus other atypical antipsychotics for schizophrenia","volume":"CD006633","author":"Asenjo Lobos","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib6","first-page":"1","article-title":"Dissecting the functional outcomes of first episode schizophrenia spectrum disorders: a 10-year follow-up study in the PAFIP cohort","author":"Ayesa-Arriola","year":"2019","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fpsyt.2019.00067","article-title":"Predictive factors of treatment resistance in first episode of psychosis: a systematic review","volume":"10","author":"Bozzatello","year":"2019","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib8","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/schbul\/8.3.470","article-title":"Measurement of premorbid adjustment in chronic schizophrenia","volume":"8","author":"Cannon-Spoor","year":"1982","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib9","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/schbul\/sbaa145","article-title":"Predictors of treatment-resistant and clozapine-resistant schizophrenia: a 12-year follow-up study of first-episode schizophrenia-spectrum disorders","volume":"47","author":"Chan","year":"2021","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000112883","article-title":"Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes","volume":"77","author":"Chouinard","year":"2008","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib11","series-title":"Stadistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"10.1016\/j.jpsychires.2022.07.015_bib12","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.MY20096AH1C","article-title":"Treatment-Resistant Schizophernia: definition, predictors and therapy options","volume":"82","author":"Correll","year":"2021","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib13","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.pnpbp.2013.02.009","article-title":"Prediction of acute clinical response following a first episode of non affective psychosis: results of a cohort of 375 patients from the Spanish PAFIP study","volume":"44","author":"Crespo-Facorro","year":"2013","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/JCP.0b013e3182825c1e","article-title":"Aripiprazole, ziprasidone, and quetiapine in the treatment of first-episode nonaffective psychosis: results of a 6-week, randomized, flexible-dose, open-label comparison","volume":"33","author":"Crespo-Facorro","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib15","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.4088\/JCP.v67n1004","article-title":"A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis","volume":"67","author":"Crespo-Facorro","year":"2006","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.psychres.2019.03.029","article-title":"Psychiatrists' attitude towards the use of clozapine in the treatment of refractory schizophrenia: a nationwide survey","volume":"275","author":"Daod","year":"2019","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib17","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.biopsych.2013.06.011","article-title":"Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function","volume":"75","author":"Demjaha","year":"2014","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib18","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1017\/S0033291717000435","article-title":"Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors","volume":"47","author":"Demjaha","year":"2017","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib19","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1176\/appi.ajp.2012.12010144","article-title":"Dopamine synthesis capacity in patients with treatment-resistant schizophrenia","volume":"169","author":"Demjaha","year":"2012","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.psychres.2012.10.011","article-title":"Predictors of clinical remission following a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables","volume":"206","author":"D\u00edaz","year":"2013","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib21","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/JCP.0000000000000734","article-title":"Clozapine use in a cohort of first-episode psychosis","volume":"37","author":"Doyle","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib22","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1192\/bjp.182.6.505","article-title":"Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK","volume":"182","author":"Duggan","year":"2003","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2022.07.015_bib23","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)","volume":"285","year":"2001","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib24","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1192\/bjp.bp.110.088690","article-title":"Clozapine: dangerous orphan or neglected friend?","volume":"198","author":"Farooq","year":"2011","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2022.07.015_bib25","series-title":"Structured Clinical Interview for DSM-IV Axis I Disorders, Clinical Version (SCID-CV)","author":"First","year":"1996"},{"key":"10.1016\/j.jpsychires.2022.07.015_bib26","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1176\/appi.ps.201400558","article-title":"Early predictors of ten-year course in first-episode psychosis","volume":"67","author":"Friis","year":"2016","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1037\/a0024338","article-title":"Effect size estimates: current use, calculations, and interpretation","volume":"141","author":"Fritz","year":"2012","journal-title":"J. Exp. Psychol. Gen."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib28","series-title":"ECDEU Assessment Manual for Psychopharmacology. U.S. Dept. Of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration","author":"Guy","year":"1976"},{"key":"10.1016\/j.jpsychires.2022.07.015_bib29","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1192\/bjp.bp.111.105833","article-title":"Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation","volume":"201","author":"Howes","year":"2012","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2022.07.015_bib30","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1017\/S0033291716002014","article-title":"Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses","volume":"46","author":"Lally","year":"2016","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib31","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jpsychires.2022.07.015_bib32","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.4088\/JCP.v67n1120","article-title":"Measurement-based psychiatry: definitions of response, remission, stability, and relapse in schizophrenia","volume":"67","author":"Leucht","year":"2006","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib33","first-page":"5","article-title":"Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU side effect rating scale (UKU-SERS-Pat)","volume":"55","author":"Lindstr\u00f6m","year":"2001","journal-title":"Nord. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib34","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/schbul\/12.4.578","article-title":"Symptom monitoring in the rehabilitation of schizophrenic patients","volume":"12","author":"Lukoff","year":"1986","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib35","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1001\/jamapsychiatry.2019.1702","article-title":"Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics: a systematic review and meta-analysis of cohort studies","volume":"76","author":"Masuda","year":"2019","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib36","first-page":"401","article-title":"Real-World antipsychotic treatment practices","volume":"30","author":"Moore","year":"2007","journal-title":"Psychiatr. Clin."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib37","doi-asserted-by":"crossref","first-page":"606","DOI":"10.4088\/JCP.12r08064","article-title":"Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?","volume":"74","author":"Nielsen","year":"2013","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib38","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1751-7893.2008.00074.x","article-title":"Epidemiological factors associated with treated incidence of first-episode non-affective psychosis in Cantabria: insights from the clinical programme on early phases of psychosis","volume":"2","author":"Pelayo-Ter\u00e1n","year":"2008","journal-title":"Early Intervention in Psychiatry"},{"key":"10.1016\/j.jpsychires.2022.07.015_bib39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1017\/S1461145713001053","article-title":"Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors","volume":"17","author":"P\u00e9rez-Iglesias","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib40","first-page":"456","article-title":"The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research","volume":"18","author":"Potkin","year":"2020","journal-title":"Am. Psychiatr. Publ."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib41","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3389\/fpsyt.2018.00327","article-title":"Biological predictors of clozapine response: a systematic review","volume":"9","author":"Samanaite","year":"2018","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib42","first-page":"1","article-title":"Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis","author":"Siskind","year":"2021","journal-title":"Br. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib43","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1177\/0706743717718167","article-title":"Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis","volume":"62","author":"Siskind","year":"2017","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1017\/S0033291719002083","article-title":"Predictors of treatment resistant schizophrenia: a systematic review of prospective observational studies","volume":"51","author":"Smart","year":"2021","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib45","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.rpsm.2021.01.004","article-title":"Comparison of aripiprazole and risperidone effectiveness in first episode non-affective psychosis: rationale and design of a prospective, randomized, 3-phase, investigator-initiated study (PAFIP-3)","volume":"14","author":"Son","year":"2021","journal-title":"Rev. Psiquiat\u00eda Salud Ment."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib46","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.psychres.2015.02.021","article-title":"Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia","volume":"227","author":"Suzuki","year":"2015","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib47","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/0006-3223(94)91259-9","article-title":"Clozapine response in treatment-refractory first-episode schizophrenia","volume":"35","author":"Szymanski","year":"1994","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib48","doi-asserted-by":"crossref","first-page":"e1447","DOI":"10.4088\/JCP.15m10063","article-title":"Clozapine use in first-episode psychosis: the Singapore early psychosis intervention programme (EPIP) perspective","volume":"77","author":"Tang","year":"2016","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib49","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.schres.2018.02.054","article-title":"Clozapine use in early psychosis","volume":"199","author":"Thien","year":"2018","journal-title":"Schizohrenia Res."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib50","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","article-title":"Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia","volume":"74","author":"Tiihonen","year":"2017","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib51","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1055\/s-0042-116947","article-title":"Time to initiation of clozapine treatment in children and adolescents with early-onset schizophrenia","volume":"49","author":"Trinczek","year":"2016","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jpsychires.2022.07.015_bib52","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/YIC.0000000000000086","article-title":"Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia","volume":"30","author":"\u00dc\u00e7ok","year":"2015","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib53","first-page":"221","article-title":"Brief Psychiatric Rating Scale (BPRS) expanded version (4.0) scales, anchor points and administration manual","volume":"13","author":"Ventura","year":"1993","journal-title":"Int. J. Methods Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib54","first-page":"281","article-title":"Clozapine as treatment of first choice in first psychotic episodes. What do we know?","volume":"40","author":"Vera","year":"2012","journal-title":"Actas Esp. Psiquiatr."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib55","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1471-244X-14-102","article-title":"Clozapine: a review of clinical practice guidelines and prescribing trends","volume":"14","author":"Warnez","year":"2014","journal-title":"BMC Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib56","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S2215-0366(15)00575-1","article-title":"Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study","volume":"3","author":"Wimberley","year":"2016","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.07.015_bib57","first-page":"1","article-title":"Predictors of remission during acute treatment of first-episode schizophrenia patients involuntarily hospitalized and treated with algorithm-based pharmacotherapy: secondary analysis of an observational study","author":"Yoshimura","year":"2017","journal-title":"Early Intervention in Psychiatry"},{"key":"10.1016\/j.jpsychires.2022.07.015_bib58","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for Mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br. J. Psychiatry"}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002239562200379X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002239562200379X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T11:31:44Z","timestamp":1758367904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002239562200379X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":58,"alternative-id":["S002239562200379X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2022.07.015","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Naturalistic study on the use of clozapine in the early phases of non-affective psychosis: A 10-year follow-up study in the PAFIP-10 cohort","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2022.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}